Your browser doesn't support javascript.
loading
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.
Tomasini, Pascale; Mascaux, Celine; Jao, Kevin; Labbe, Catherine; Kamel-Reid, Suzanne; Stockley, Tracy; Hwang, David M; Leighl, Natasha B; Liu, Geoffrey; Bradbury, Penelope A; Pintilie, Melania; Tsao, Ming-Sound; Shepherd, Frances A.
Afiliação
  • Tomasini P; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de
  • Mascaux C; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada; Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de
  • Jao K; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Labbe C; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Kamel-Reid S; Department of Pathology, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Stockley T; Department of Pathology, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Hwang DM; Department of Pathology, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Leighl NB; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Liu G; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Bradbury PA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Pintilie M; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Tsao MS; Department of Pathology, University Health Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Shepherd FA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.
Clin Lung Cancer ; 20(3): e338-e345, 2019 05.
Article em En | MEDLINE | ID: mdl-30770327

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas p21(ras) / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Mutação Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína Supressora de Tumor p53 / Proteínas Proto-Oncogênicas p21(ras) / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Mutação Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article